Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2630)	10/13/2009 9:49:17 AM
From: Jibacoa	Respond to of 3722

VNDA wants to resume its uptrend without closing its May 6 UG bigcharts.marketwatch.com It announced yesterday evening that it has entered into an agreement with Novartis to commercialize Fanapt, its anti-psychotic drug , in the U.S. and Canada. The drug was already approved by the FDA on May 6 for the acute treatment of schizophrenia in adults.The anti-psychotic market in the US is estimated at approximately $14B <g> The stock is starting to get off from its near term DT coming from its Aug 5 at $16.65 bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2630)	6/7/2010 5:50:10 PM
From: Jibacoa	1 Recommendation Respond to of 3722

VASC so far hasn't been affected by the May-June "market correction." <g> It has been able to hold the UT after the L at $5 in March last Yr. bigcharts.marketwatch.com Today it was able to hold its support at the $11 level and closed up 2.36% on volume about 1.4x its ADV On May 3, VASC acquired the assets related to the SMARTNEEDLE and pdACCESS Doppler guided needle business from ESMC, which are designed to provide auditory ultrasound guided access to arteries and veins during cath procedures. The annualized sales of the combined products is approximately $3.8M. The acquisition price was $5.75M The ACTAY is $13 VASC has no significant LTD and has +CF It seems that with further good news and a better general market, the stock shouldn't have much problem in getting back to the $15 level.<g> bigcharts.marketwatch.com Bernard